The Expression of Interferon Receptor α/β in Human Pancreatic Cancer in Nude Mice is Essential for Tumor Response to Interferon α Treatment

被引:3
作者
Saidi, Reza F. [1 ]
Ahad, Ahmad [2 ]
Tilak, Jacqueline [2 ]
Nalbantoglu, Ilke [3 ]
Jacobs, Michael J. [2 ]
机构
[1] Univ Massachusetts, Sch Med, Div Organ Transplantat, Dept Surg, Worcester, MA 01605 USA
[2] Providence Hosp & Med Ctr, Dept Surg, Southfield, MA USA
[3] St Johns Hosp, Dept Pathol, Detroit, MI USA
关键词
pancreatic cancer; interferon; interferon receptor; PHASE-II TRIAL; ONCOLOGY-GROUP; 5-FLUOROURACIL; ADENOCARCINOMA; CARCINOMA; ACID; PANCREATICODUODENECTOMY; IDENTIFICATION; LEUCOVORIN; INFUSION;
D O I
10.1016/j.jss.2010.09.044
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Adjuvant interferon based chemoradiation has rendered promising results against pancreatic cancer. This study evaluated the in vivo effect of interferon alpha on two human pancreatic carcinoma cell lines implanted in nude. Material and Methods. MiaPaCa-2 expressed the interferon alpha/beta receptor and Panc-1 cells did not. Regimen I consisted of intraperitoneal single-agent gemcitabine and Regimen II consisted of IFN-alpha and gemcitabine biweekly for 30 d. Results. Regimen I and II significantly decreased median tumor volume compared with control mice (P < 0.001). However, MiaPaCa-2 showed a more dramatic response to Regimen II compared with Panc-1 implanted mice. MiaPaCa-2 and treated with Regimen II showed less metastasis and less local invasion compared with Panc-1 treated with same regimen. Regimen II was more effective on MiaPaCa-2 compared with Regimen I (P < 0.001). There were no differences between Regimens I and II in the Panc-1 group. Conclusions. Treatment of human pancreatic cancer in nude mice with interferon alpha and gemcitabine was associated with a reduction in tumor volume. This process was more prominent in the cells that express the interferon receptors. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:309 / 313
页数:5
相关论文
共 27 条
  • [1] Afsari A, 2002, AM SURGEON, V68, P281
  • [2] Ahrendt SA, 2002, ONCOLOGY-NY, V16, P725
  • [3] TREATMENT OF ADVANCED PANCREATIC-CANCER WITH 5-FLUOROURACIL, FOLINIC ACID AND INTERFERON ALPHA-2A - RESULTS OF A PHASE-II TRIAL
    BERNHARD, H
    JAGERARAND, E
    BERNHARD, G
    HEIKE, M
    KLEIN, O
    RIEMANN, JF
    MEYER, KH
    DIPPOLD, W
    KNUTH, A
    [J]. BRITISH JOURNAL OF CANCER, 1995, 71 (01) : 102 - 105
  • [4] Brembeck FH, 1998, CANCER, V83, P2317, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2317::AID-CNCR11>3.0.CO
  • [5] 2-P
  • [6] Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005
  • [7] A phase II trial of 5-fluorouracil, leucovorin, and interferon alpha 2A (IFN-α 2a) in metastatic pancreatic carcinoma -: A Penn Cancer Clinical Trials Group (PCCTG) trial
    David, AK
    Vaughn, DJ
    Holroyde, CP
    Armstead, B
    Haller, DG
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (01): : 37 - 39
  • [8] de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912
  • [9] Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays
    Der, SD
    Zhou, AM
    Williams, BRG
    Silverman, RH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) : 15623 - 15628
  • [10] HOTZ HG, 2003, PANCREAS, V26, P89, DOI DOI 10.1097/00006676-200305000-00020